Mr. David L. Stern is currently the Executive Vice President of the Endocrinology Business Unit at EMD Serono, Inc. He is responsible for and leads all commercial operations for the US market in the HIV, Reproductive Health and Metabolic Endocrinology areas.

The Endocrinology therapeutic area consists of EMD Serono’s portfolio of Reproductive Health products: Gonal -f® (follitropin alfa for injection); Luveris® (lutropin alfa for injection); Ovidrel® (choriogonadotropin alfa injection); and Crinone® (progesterone gel); as well as EMD Serono’s pediatric growth hormone, Saizen® [somatropin (rDNA origin) for injection]; HIV wasting product, Serostim® [somatropin (rDNA origin) for injection]; and Zorbtive™ [somatropin (rDNA origin) for injection] for Short Bowel Syndrome. Prior to his appointment to Executive Vice President, Mr. Stern was the Vice President of Marketing for Metabolic Endocrinology for over two years. Before joining the company, Mr. Stern was the Director, Reproductive Marketing at Organon USA and was responsible for the contraceptive and fertility brands.

Mr. Stern has been involved in the pharmaceutical industry in both a sales and marketing capacity since 1993. He has launched numerous brands in the women’s health and metabolic marketplaces, both on the professional and consumer sides of the pharmaceutical business. He is an active speaker on pharmaceutical marketing and has been a member of the Board of Directors of the American Fertility Association since 1998.

Mr. Stern has a Master’s in business administration with a concentration in international marketing and management from the F.W. Olin School of Business at Babson College. He also holds a Bachelor’s Degree in biology with a minor in economics from Brandeis University.